Loading clinical trials...
Loading clinical trials...
A Phase I Trial of Imatinib, Bevacizumab, & Metronomic Cyclophosphamide as Antiangiogenic Therapy in Refractory Metastatic Solid Tumors
Conditions
Interventions
bevacizumab
cyclophosphamide
+1 more
Locations
1
United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Start Date
August 1, 2006
Primary Completion Date
January 1, 2011
Completion Date
January 1, 2011
Last Updated
July 28, 2020
NCT02293954
NCT00483366
NCT00875004
NCT02088775
NCT00107250
NCT00390117
Lead Sponsor
University of California, San Francisco
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions